Immunotherapy, gene therapy and peptide delivery

Theragene Pharmaceuticals is focused on advancing innovative treatments through its immunotherapy and gene therapy technologies. The company's immunotherapy platform aims to provide patients with a safer alternative to traditional cancer treatments by enhancing the body's natural ability to identify and combat tumor cells. This approach is designed to improve patient outcomes while minimizing the side effects commonly associated with conventional therapies.

In addition to immunotherapy, Theragene employs Adeno-Associated Virus (AAV) technology within its gene therapy platform, specifically targeting cardiovascular diseases. This technology allows for the delivery of therapeutic genes to the affected tissues, potentially offering new avenues for treatment. By leveraging these advanced technologies, Theragene Pharmaceuticals is committed to developing effective and safe therapies for both cancer and cardiovascular conditions, while also exploring collaborative opportunities to enhance its product development efforts.

United States

Theragene Pharmaceuticals is creating life-changing cancer and cardiology treatments through the development of our novel immunotherapy and Adeno-Associated Virus (AAV) gene therapy platforms.  As a company operating in both the US and Asia, we deliver unique product development models, utilizing the strengths of each region, while delivering safe, effective treatments.

Our mission is to advance cutting-edge science through efficient development plans while pursuing licensing or co-development collaborations.

Theragene Pharmaceuticals

Company Details